C1QTNF5 and atherosclerosis: The CCTA method allows the identification of patients exhibiting advanced atherosclerosis, as evidenced by increased CACS, significant calcific plaque burden, and lowered early-stage atherosclerotic plaque presence, resulting in reduced levels of CTRP5 and chemerin expression.